作者: Michael W. Weiner , Dallas P. Veitch , Paul S. Aisen , Laurel A. Beckett , Nigel J. Cairns
DOI: 10.1016/J.JALZ.2013.05.1769
关键词:
摘要: The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection tracking of disease (AD). aimed enroll 400 subjects with mild cognitive impairment (MCI), 200 AD, normal control subjects; $67 million funding was provided by both public private sectors, including National Institute on Aging, 13 pharmaceutical companies, 2 foundations that support through Foundation Institutes Health. This article reviews all papers published since inception initiative summarizes results as February 2011. major accomplishments ADNI have been follows: (1) development standardized methods clinical tests, magnetic resonance imaging (MRI), positron emission tomography (PET), cerebrospinal fluid (CSF) in a setting; (2) elucidation patterns rates change CSF biomarker measurements subjects, MCI patients, AD patients. are consistent trajectories predicted β-amyloid cascade (Hardy, J Alzheimers Dis 2006;9(Suppl 3):151-3) tau-mediated neurodegeneration hypotheses whereas brain atrophy hypometabolism levels show but exhibit differing depending region severity; (3) assessment alternative diagnostic categorization. Currently, best classifiers combine optimum features from multiple modalities, MRI, [(18)F]-fluorodeoxyglucose-PET, biomarkers, tests; (4) AD. 42 tau, well amyloid PET may reflect earliest steps pathology mildly symptomatic or even nonsymptomatic leading candidates its preclinical stages; (5) improvement trial efficiency identification most likely undergo imminent future decline use more sensitive outcome measures reduce sample sizes. Baseline and/or MRI generally better than other were shown be efficient measures; (6) confirmation risk loci CLU, CR1, PICALM novel candidate loci; (7) worldwide impact establishment ADNI-like programs Europe, Asia, Australia; (8) understanding biology pathobiology aging, MCI, integration data stimulate research will resolve controversies about competing etiopathogenesis thereby advancing efforts find disease-modifying drugs AD; (9) infrastructure allow sharing raw processed without embargo interested scientific investigators throughout world. extended 2-year Grand Opportunities grant 2009 renewal (ADNI-2) October 2010 2016, enrollment additional 550 participants.